Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 4/20 | 0.51 |
| ▸ | CNR1 | P21554 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117739 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL1503636 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL650656 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL118129 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL18297784 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL23921985 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL375162 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL18297783 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL118128 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 | |
| SCHEMBL2801944 | 1.00 | FASN (0.53) | FASNKDM4EMAPTFAAHCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 423 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11712428-B2 | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-01 | — | — | US | claimed |
| US-11712429-B2 | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-08-01 | — | — | US | claimed |
| US-11690820-B2 | Methods of treating mixed dyslipidemia | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2023-07-04 | — | — | US | claimed |
| CN-115466180-A | Method for purifying eicosapentaenoic acid ethyl ester | 江苏海莱康生物科技有限公司 | 2022-12-13 | — | — | CN | claimed |
| US-20200360330-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2020-11-19 | — | — | US | claimed |
| EP-3583849-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | Amarin Pharmaceuticals Ireland Limited (IE) | 2019-12-25 | — | — | EP | claimed |
| EP-2542060-B1 | COMPOSITIONS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMACEUTICALS IE LTD (IE) | 2019-10-02 | — | — | EP | claimed |
| US-20170128406-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2017-05-11 | — | — | US | claimed |
| US-20150335607-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2015-11-26 | — | — | US | claimed |
| US-20140128464-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2014-05-08 | — | — | US | claimed |
| US-8455472-B2 | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy | AMARIN PHARMACEUTICALS IRELAND LIMITED (IE) | 2013-06-04 | — | — | US | claimed |
| EP-2542060-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | Amarin Pharma, Inc. (US) | 2013-01-09 | — | — | EP | claimed |
| EP-2443246-A1 | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISING LDL-C LEVELS IN A SUBJECT ON CONCOMITANT STATIN THERAPY | Osterloh, Ian (US) | 2012-04-25 | — | — | EP | claimed |
| WO-2011109724-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMA, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| US-20110218243-A1 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | AMARIN PHARMA, INC. (US) | 2011-09-08 | — | — | US | claimed |
| US-20110034555-A1 | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISING LDL-C LEVELS IN A SUBJECT ON CONCOMITANT STATIN THERAPY | AMARIN PHARMA , INC. (US) | 2011-02-10 | — | — | US | claimed |
| WO-2010147994-A1 | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISING LDL-C LEVELS IN A SUBJECT ON CONCOMITANT STATIN THERAPY | AMARIN PHARMA, INC. (US) | 2010-12-23 | — | — | WO | claimed |
| EP-3196280-B1 | COMPOSITION CONTAINING EICOSAPENTAENOIC ACID ALKYL ESTER, AND METHOD FOR PRODUCING SAME | NISSUI CORP (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-20080200707-A1 | Lipotoxicity Relieving Agent | MOCHIDA-PHARMACEUTICALS PHARMACEUTICAL CO., LTD. (JP) | 2008-08-21 | — | — | US | disclosed |
| EP-1834639-A1 | REMEDIAL AGENT FOR FAT TOXICITY | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2007-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690820-B2 | Methods of treating mixed dyslipidemia | LIPA, LIPC, PNLIP | FASN 49/4885KDM4E 2721/4885MAPT 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.